Completed PHASE2 INTERVENTIONAL 8-arm NCT00685399

Safety and Efficacy of AIN457 in Noninfectious Uveitis

An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis

Sponsor: Novartis Pharmaceuticals

Conditions Non-infectious Uveitis

Interventions AIN 457 AIN457

Updated 7 times since 2017 Last updated: Jun 15, 2017 Started: Jun 30, 2008 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-infectious Uveitis, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Aug 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Aug 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arlington, United States , Atlanta, United States , Austin, United States , Baltimore, United States , Berlin, Germany , Beverly Hills, United States , Cambridge, United States , Cleveland, United States , Denver, United States , Durham, United States and 12 more locations